2.38
+0.01 (+0.42%)
Taking everything into account, HTBX scores 2 out of 10 in our fundamental rating. HTBX was compared to 525 industry peers in the Biotechnology industry. HTBX may be in some trouble as it scores bad on both profitability and health. HTBX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- HTBX had negative earnings in the past year.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.99% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- HTBX does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | -1658.78% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- HTBX has more shares outstanding than it did 1 year ago.
- HTBX has a worse debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 2.71 indicates that HTBX is not a great score, but indicates only limited risk for bankruptcy at the moment.
- A Debt/Equity ratio of 0.00 indicates that HTBX is not too dependend on debt financing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.71 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- HTBX has a Current Ratio of 21.04. This indicates that HTBX is financially healthy and has no problem in meeting its short term obligations.
- A Quick Ratio of 21.04 indicates that HTBX has no problem at all paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 21.04 | ||
| Quick Ratio | 21.04 |
3. Growth
3.1 Past
- HTBX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.62%, which is quite good.
- The Revenue for HTBX has decreased by -28.09% in the past year. This is quite bad
- The Revenue has been growing by 44.10% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)9.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2600%
Revenue 1Y (TTM)-28.09%
Revenue growth 3Y-28.54%
Revenue growth 5Y44.1%
Sales Q2Q%2.18%
3.2 Future
- The Earnings Per Share is expected to decrease by -0.56% on average over the next years.
- The Revenue is expected to grow by 136.46% on average over the next years. This is a very strong growth
EPS Next Y-23.7%
EPS Next 2Y-3.24%
EPS Next 3Y10.19%
EPS Next 5Y-0.56%
Revenue Next Year128.57%
Revenue Next 2Y55.11%
Revenue Next 3Y129.35%
Revenue Next 5Y136.46%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- HTBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year HTBX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.04 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.24%
EPS Next 3Y10.19%
5. Dividend
5.1 Amount
- No dividends for HTBX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HEAT BIOLOGICS INC / HTBX FAQ
What is the ChartMill fundamental rating of HEAT BIOLOGICS INC (HTBX) stock?
ChartMill assigns a fundamental rating of 4 / 10 to HTBX.
What is the valuation status for HTBX stock?
ChartMill assigns a valuation rating of 3 / 10 to HEAT BIOLOGICS INC (HTBX). This can be considered as Overvalued.
How profitable is HEAT BIOLOGICS INC (HTBX) stock?
HEAT BIOLOGICS INC (HTBX) has a profitability rating of 1 / 10.